Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00119652 · ClinicalTrials.gov registry record · Phase 3
Seroquel in Bipolar Depression Versus SSRI
A Phase 3 study of Depression and Bipolar Disorder, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 676
- Enrollment target
- 20
- Study locations
NCT00119652: Completed Phase 3 study of Depression and Bipolar Disorder, sponsored by AstraZeneca.
NCT00119652 is a Phase 3 study of Depression and Bipolar Disorder that has completed, run by AstraZeneca. The registered enrollment target is 676 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00119652, a Phase 3 study of Depression and Bipolar Disorder, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 676 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
Conditions Studied
Interventions
- DRUG paroxetine
- DRUG quetiapine fumarate (Seroquel)
- BEHAVIORAL mood stabilizing activity
Study Locations (20)
California
- Research Site - National City
- Research Site - San Clemente
- Research Site - San Diego
Florida
- Research Site - Maitland
- Research Site - Winter Park
Georgia
- Research Site - Atlanta
- Research Site - Smyrna
Illinois
- Research Site - Northfield
- Research Site - Oak Brook
Louisiana
- Research Site - New Orleans
- Research Site - Shreveport
Ohio
- Research Site - Cincinnati
- Research Site - Dayton
Arizona
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 676 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
What the finished NCT00119652 record still lists
NCT00119652 is an interventional study that assigns participants to a tested intervention. The registered 676 participants enrollment target is mid-sized for trials with a published cap, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which paroxetine is the first listed.
NCT00119652 names 20 study sites across 13 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00119652 about?
NCT00119652 is a clinical study titled "Seroquel in Bipolar Depression Versus SSRI". The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
What is the current status of trial NCT00119652?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 676 participants. The study started on 2005-05. Estimated completion is 2007-05.
What conditions does trial NCT00119652 study?
This clinical trial studies the following conditions: Depression, Bipolar Disorder, Bipolar Depression.
What interventions are being tested in trial NCT00119652?
The interventions under investigation include: paroxetine (DRUG), quetiapine fumarate (Seroquel) (DRUG), mood stabilizing activity (BEHAVIORAL).
Who is sponsoring clinical trial NCT00119652?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00119652 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00119652's enrollment target sits among peer trials
676 59th of 679 higher than 620 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04788277 · 675 participants
Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)
- NCT05356234 · 675 participants · NA
Ignite Study of the Jewish Family and Children's Service of the Suncoast, Inc.
- NCT06070870 · 675 participants · NA
Health Education Approach to Lung Screening
- NCT06357533 · 675 participants · Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia